Doctor's DEA License Yanked for Illegal Prescribing Post-License Loss
Published Date: 5/7/2025
Notice
Summary
Dr. Peter Dashkoff from Arizona had his DEA registration suspended because he wrote controlled substance prescriptions when he wasn’t allowed to practice medicine. After reviewing the case, the DEA decided to revoke his registration to keep the public safe. This means Dr. Dashkoff can no longer legally prescribe certain medications, affecting his medical practice and patients immediately.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
DEA Revokes Doctor’s Controlled‑Substance License
The DEA revoked Peter Dashkoff, M.D.'s DEA Certificate of Registration No. FD3660304, effective June 6, 2025, so he can no longer legally prescribe controlled substances. The Order also denies any pending applications to renew or modify his registration and any other pending application for additional registration in the State of Arizona. The record shows he issued four controlled‑substance prescriptions (two morphine Schedule II and two lorazepam Schedule IV) after his Arizona authority lapsed on June 26, 2024.
DEA Action Intended to Deter Prescribing Violations
The Agency explained it revoked the registration in part to deter similar conduct by other registrants and to protect the public from diversion of controlled substances. The decision states the sanction is meant to "send a message to all registrants" that prescribing without state authority is taken seriously.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
Previous / Next Documents
Previous: 2025-07932 — Agency Collection Activities; Requesting Comments on Form 5316
The IRS wants your thoughts on Form 5316, which helps groups apply for special tax rules. This is a chance for anyone affected—like trusts and their managers—to suggest ways to make the form easier and less time-consuming. Comments are open now, so jump in before the deadline to help shape the process and possibly save time and hassle!
Next: 2025-07934 — Margaret Dennis, D.M.D.; Default Decision and Order
Dr. Margaret Dennis from Jacksonville, FL, lost her DEA license because she prescribed controlled drugs without proper medical reasons and ignored warning signs for over 11 years. Since she didn’t ask for a hearing, her license is officially revoked to protect public safety. This means she can’t legally prescribe these drugs anymore, effective immediately.